Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

<p>Phosphoproteins</p>

Enregistré dans:
Détails bibliographiques
Auteur principal: Xiaoqing Cheng (16918496) (author)
Autres auteurs: Yirui Sun (16918499) (author), Maureen Highkin (16918502) (author), Nagalaxmi Vemalapally (16918505) (author), Xiaohua Jin (16918508) (author), Brandon Zhou (16918511) (author), Julie L. Prior (16918514) (author), Ashley R. Tipton (16918517) (author), Shunqiang Li (15123195) (author), Anton Iliuk (16918520) (author), Samuel Achilefu (11605234) (author), Ian S. Hagemann (15026769) (author), John R. Edwards (16918523) (author), Ron Bose (15045749) (author)
Publié: 2025
Sujets:
Cancer
Molecular and Cellular Biology
Therapeutic Research and Development
Methods and Technology
Biological Agents & Therapies
Antibody-drug conjugates
Antireceptors
Breast Cancer
Cell Cycle
CDKs and CDK inhibitors
Preclinical Models
Organoids
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:<p>Phosphoproteins</p>

Documents similaires